Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

VERA Vera Therapeutics, Inc.

Closed Good Friday 04-17 16:00:00 EDT

21.29

+0.05

+0.24%

盘后21.29

+0.000.00%

18:00 EDT

High21.79	Low20.98	Vol661.23K
Open21.16	D1 Closing21.24	Amplitude3.83%
Mkt Cap1.36B	Tradable Cap1.08B	Total Shares63.75M
T/O14.03M	T/O Rate1.31%	Tradable Shares50.54M
P/B2.35	ROE-44.83%	EPS-2.75
52wk High51.61	52wk Low18.53	P/E-7.74
Dividend0.00	Div.Yield0.00	ROA-25.14%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"VERA","market":"US","secType":"STK","nameCN":"Vera Therapeutics, Inc.","latestPrice":21.29,"timestamp":1744920000000,"preClose":21.24,"halted":0,"volume":661231,"hourTrading":{"tag":"盘后","latestPrice":21.29,"preClose":21.29,"latestTime":"18:00 EDT","volume":21425,"amount":456184.8,"timestamp":1744927221619},"delay":0,"floatShares":50540109,"shares":63748290,"eps":-2.749993,"marketStatus":"Closed Good Friday","change":0.05,"latestTime":"04-17 16:00:00 EDT","open":21.16,"high":21.7925,"low":20.98,"amount":14028621.352596,"amplitude":0.038253,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.749993,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1620964800000,"exchange":"NASDAQ","adjPreClose":21.24,"preHourTrading":{"tag":"盘前","latestPrice":20.94,"preClose":21.24,"latestTime":"04:53 EDT","volume":4,"amount":83.35,"timestamp":1744880029115},"postHourTrading":{"tag":"盘后","latestPrice":21.29,"preClose":21.29,"latestTime":"18:00 EDT","volume":21425,"amount":456184.8,"timestamp":1744927221619},"volumeRatio":0.741938120078196,"impliedVol":0.8313,"impliedVolPercentile":0.7928},"requestUrl":"/m/hq/s/VERA","defaultTab":"news","newsList":[{"id":"2526349814","title":"Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2526349814","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526349814?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 04:05","pubTimestamp":1744229100,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., April 09, 2025  -- Vera Therapeutics, Inc.  today announced that on April 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 211,250 shares of Class A common stock and restricted stock units  for 105,125 shares of Class A common stock to sixteen  new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vera-therapeutics-reports-inducement-grants-200500172.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4213","NVIW.SI","TQQQ","BK4139","BK4007","BK4588","QLD","NDAQ","QID","LENZ","IE00BKPKM429.USD","BK4585","SQQQ","VERA","IE00B64PRP62.GBP","USAW.SI","USJW.SI","LU2210150020.SGD","PSQ","TSYW.SI","BKV","IE00B3QW5Z07.USD","NQmain","IE00BGHQF748.EUR",".IXIC","LU2095319765.USD","MNQmain","BK4112","LU2210149790.SGD"],"gpt_icon":1},{"id":"2526845349","title":"Kidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch","url":"https://stock-news.laohu8.com/highlight/detail?id=2526845349","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526845349?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 02:51","pubTimestamp":1744224699,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc. said on Wednesday that it had completed full enrollment  in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy .ORIGIN 3 follows the long-term results from the ORIGIN Phase 2b trial, which demonstrated sustained and substantial reductions in Gd-IgA1, hematuria, and proteinuria and showed stabilized kidney function through 96 weeks.Also Read: Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years. Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Vera Therapeutics, an investor could make an assessment about a stock's long term prospects using a moving average and trend line. If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Vera Therapeutics, the 200-day moving average","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kidney-disease-focused-vera-therapeutics-185139057.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VERA","BK4588","BK4539","LENZ","BK4007","BK4585","BK4139"],"gpt_icon":0},{"id":"2525128320","title":"Guggenheim Reaffirms Their Buy Rating on Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2525128320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525128320?lang=en_us&edition=full_marsco","pubTime":"2025-04-07 19:35","pubTimestamp":1744025744,"startTime":"0","endTime":"0","summary":"In a report released today, Vamil Divan from Guggenheim reiterated a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-vera-therapeutics-vera?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-reaffirms-their-buy-rating-on-vera-therapeutics-vera?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA"],"gpt_icon":0},{"id":"2524926072","title":"Positive Outlook for Vera Therapeutics: Buy Rating on Atacicept’s Potential in IgA Nephropathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2524926072","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524926072?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 23:45","pubTimestamp":1743695110,"startTime":"0","endTime":"0","summary":"Rami Katkhuda, an analyst from LifeSci Capital, maintained the Buy rating on Vera Therapeutics (VERA – Research Report). The associated price targe...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-for-vera-therapeutics-buy-rating-on-atacicepts-potential-in-iga-nephropathy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-for-vera-therapeutics-buy-rating-on-atacicepts-potential-in-iga-nephropathy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA","LENZ"],"gpt_icon":0},{"id":"2524259899","title":"Vera Therapeutics completes enrollment in ORIGIN Phase 3 trial for atacicept","url":"https://stock-news.laohu8.com/highlight/detail?id=2524259899","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524259899?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 20:10","pubTimestamp":1743682254,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Neph...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-completes-enrollment-in-origin-phase-3-trial-for-atacicept?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-completes-enrollment-in-origin-phase-3-trial-for-atacicept?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","LENZ","VERA","BK4139","BK4588","BK4539"],"gpt_icon":0},{"id":"2524256378","title":"Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN","url":"https://stock-news.laohu8.com/highlight/detail?id=2524256378","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524256378?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 20:00","pubTimestamp":1743681600,"startTime":"0","endTime":"0","summary":"On track to announce primary endpoint result from ORIGIN 3 trial this quarter . U.S. FDA BLA submission for accelerated approval planned for 2H 2025. BRISBANE, Calif., April 03, 2025  -- Vera Therapeutics, Inc. , a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it has completed full enrollment in the pivotal ORIGIN Phase 3 trial of atacicept in patients with IgA Nephropathy .About Atacicept Atacicept is an investigational recombinant fusion protein that contains the soluble transmembrane activator and calcium-modulating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vera-therapeutics-completes-full-enrollment-120000786.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VERA","BKV","TACI","BK4139","LENZ","BK4213"],"gpt_icon":0},{"id":"2518772355","title":"Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2518772355","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518772355?lang=en_us&edition=full_marsco","pubTime":"2025-03-12 04:28","pubTimestamp":1741724880,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., March  11, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on March 6, 2025, the Compensation Committee granted inducement awards consisting of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/11/3041025/0/en/Vera-Therapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSQ","TQQQ","BK4112","VERA","QID","IE00BKPKM429.USD","IE00B3QW5Z07.USD","LENZ","SQQQ","MNQmain","BK4213","BK4588","BKV",".IXIC","LU2095319765.USD","BK4585","QLD","TSYW.SI","IE00BGHQF748.EUR","IE00B64PRP62.GBP","USJW.SI","BK4139","LU2210150020.SGD","LU2210149790.SGD","NDAQ","USAW.SI","NVIW.SI","NQmain"],"gpt_icon":1},{"id":"1132052591","title":"Stock Track | Vera Therapeutics Soars 5.21% on Buy Rating and Price Target Increase from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=1132052591","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132052591?lang=en_us&edition=full_marsco","pubTime":"2025-03-06 04:54","pubTimestamp":1741208059,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc.  stock soared 5.21% in intraday trading on Wednesday, following a Buy rating and price target increase from TD Cowen analyst Ritu Baral.In a research report released today, Baral maintained a Buy rating on VERA and raised the price target, citing the company's promising drug pipeline and potential for significant growth. The analyst's positive outlook on VERA's prospects has boosted investor confidence, driving the stock price higher.Vera Therapeutics is a biopharmaceutic","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Vera Therapeutics Soars 5.21% on Buy Rating and Price Target Increase from TD Cowen","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VERA"],"gpt_icon":0},{"id":"2517991122","title":"Vera Therapeutics (VERA) Gets a Buy from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2517991122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517991122?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 21:19","pubTimestamp":1741180741,"startTime":"0","endTime":"0","summary":"In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-gets-a-buy-from-td-cowen-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vera-therapeutics-vera-gets-a-buy-from-td-cowen-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4566","TD","VERA","BK4207","BK4139","BK4127","BK4539","BK4585","COWN","BK4588"],"gpt_icon":0},{"id":"2517160796","title":"Vera Therapeutics Is Maintained at Overweight by JP Morgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2517160796","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517160796?lang=en_us&edition=full_marsco","pubTime":"2025-03-05 02:04","pubTimestamp":1741111440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 04, 2025 13:04 ET (18:04 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","VERA"],"gpt_icon":0},{"id":"2516673392","title":"Vera Therapeutics price target lowered to $71 from $77 at JPMorgan","url":"https://stock-news.laohu8.com/highlight/detail?id=2516673392","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516673392?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:14","pubTimestamp":1741090448,"startTime":"0","endTime":"0","summary":"JPMorgan analyst Anupam Rama lowered the firm’s price target on Vera Therapeutics (VERA) to $71 from $77 and keeps an Overweight rating on the shar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-lowered-to-71-from-77-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-price-target-lowered-to-71-from-77-at-jpmorgan?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA","LENZ"],"gpt_icon":0},{"id":"1110243071","title":"Stock Track | Vera Therapeutics Soars 5.08% on Analyst Updates and Conference Participation","url":"https://stock-news.laohu8.com/highlight/detail?id=1110243071","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110243071?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 00:04","pubTimestamp":1740672287,"startTime":"0","endTime":"0","summary":"Vera Therapeutics, Inc.  saw its stock soar 5.08% in intraday trading on Thursday, driven by a series of analyst updates and the company's announcement of its participation in an upcoming healthcare conference.Wedbush adjusted its price target on Vera Therapeutics' stock from $38 to $34 while maintaining a Neutral rating. Additionally, other analysts provided insights and ratings on the company, potentially influencing investor sentiment.Furthermore, Vera Therapeutics announced that its manageme","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Vera Therapeutics Soars 5.08% on Analyst Updates and Conference Participation","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VERA"],"gpt_icon":0},{"id":"2514384166","title":"Vera Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2514384166","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514384166?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 23:55","pubTimestamp":1740671700,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/VERA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2025 10:55 ET (15:55 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","VERA"],"gpt_icon":0},{"id":"2514756800","title":"Wedbush Adjusts Price Target on Vera Therapeutics to $34 From $38, Maintains Neutral Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2514756800","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514756800?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 22:04","pubTimestamp":1740665084,"startTime":"0","endTime":"0","summary":"Vera Therapeutics (VERA) has an average rating of buy and mean price target of $68.08, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["VERA","LENZ"],"gpt_icon":0},{"id":"2514587804","title":"Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2514587804","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514587804?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 21:00","pubTimestamp":1740661200,"startTime":"0","endTime":"0","summary":"BRISBANE, Calif., Feb.  27, 2025  (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3033792/0/en/Vera-Therapeutics-to-Participate-in-the-TD-Cowen-45th-Annual-Health-Care-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","BK4127","BK4585","BK4588","BK4539","BKV","BK4213","BK4566","VERA","COWN","LENZ","BK4139","TD"],"gpt_icon":0},{"id":"2514280900","title":"Vera Therapeutics Inc : Raymond James Cuts Target Price to $73 From $76","url":"https://stock-news.laohu8.com/highlight/detail?id=2514280900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514280900?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 20:45","pubTimestamp":1740660331,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1OG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VERA","BK4588","BK4539","BK4585"],"gpt_icon":0},{"id":"2514803727","title":"Vera Therapeutics Inc : Guggenheim Raises Target Price to $61 From $59","url":"https://stock-news.laohu8.com/highlight/detail?id=2514803727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514803727?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 19:59","pubTimestamp":1740657564,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI1G0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4585","VERA","BK4539","BK4588"],"gpt_icon":0},{"id":"2514874774","title":"Analysts Offer Insights on Healthcare Companies: Agilent (A) and Vera Therapeutics (VERA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514874774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514874774?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 18:40","pubTimestamp":1740652806,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agilent (A – Research Report) and Vera Therapeutics (VERA – Resea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-agilent-a-and-vera-therapeutics-vera?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-agilent-a-and-vera-therapeutics-vera?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1165135440.EUR","LU1543694498.USD","IE00BN0W2T93.GBP","BK4121","BK4539","LU2413666426.HKD","BK4137","BK4567","BK4585","LU1721428933.USD","HCSG","IE00BN0W2W23.USD","A","IE00BN0W2V16.EUR","LU0347712357.USD","BK4139","VERA","BK4588","LU2092937221.SGD","LU2413666699.HKD","LU2041044095.USD"],"gpt_icon":0},{"id":"2514864859","title":"Optimistic Buy Rating for Vera Therapeutics: Strong Financials and Promising Pipeline Drive Positive Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2514864859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514864859?lang=en_us&edition=full_marsco","pubTime":"2025-02-27 03:25","pubTimestamp":1740597917,"startTime":"0","endTime":"0","summary":"In a report released today, Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics (VERA – Research Report), with a price ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-vera-therapeutics-strong-financials-and-promising-pipeline-drive-positive-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-buy-rating-for-vera-therapeutics-strong-financials-and-promising-pipeline-drive-positive-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VERA","LENZ"],"gpt_icon":0},{"id":"2514683028","title":"Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M","url":"https://stock-news.laohu8.com/highlight/detail?id=2514683028","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514683028?lang=en_us&edition=full_marsco","pubTime":"2025-02-26 21:35","pubTimestamp":1740576914,"startTime":"0","endTime":"0","summary":"Earnings Flash (VERA) Vera Therapeutics Posts Full Year 2024 Total Operating Expenses $167.2M","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSS","VERA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.veratx.com","stockEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.2213},{"period":"3month","weight":-0.362},{"period":"6month","weight":-0.4828},{"period":"1year","weight":-0.4679},{"period":"ytd","weight":-0.4966}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.108417},{"month":2,"riseRate":0.5,"avgChangeRate":0.034073},{"month":3,"riseRate":0.5,"avgChangeRate":-0.056274},{"month":4,"riseRate":0,"avgChangeRate":-0.122248},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.018611},{"month":6,"riseRate":0.25,"avgChangeRate":0.144811},{"month":7,"riseRate":1,"avgChangeRate":0.20143},{"month":8,"riseRate":0.5,"avgChangeRate":0.013669},{"month":9,"riseRate":0.5,"avgChangeRate":0.025362},{"month":10,"riseRate":0.25,"avgChangeRate":-0.084104},{"month":11,"riseRate":0.75,"avgChangeRate":0.31962},{"month":12,"riseRate":0.5,"avgChangeRate":-0.027461}],"exchange":"NASDAQ","name":"Vera Therapeutics, Inc.","nameEN":"Vera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Vera Therapeutics, Inc.,VERA,Vera Therapeutics, Inc.股票,Vera Therapeutics, Inc.股票老虎,Vera Therapeutics, Inc.股票老虎国际,Vera Therapeutics, Inc.行情,Vera Therapeutics, Inc.股票行情,Vera Therapeutics, Inc.股价,Vera Therapeutics, Inc.股市,Vera Therapeutics, Inc.股票价格,Vera Therapeutics, Inc.股票交易,Vera Therapeutics, Inc.股票购买,Vera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vera Therapeutics, Inc.(VERA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Vera Therapeutics, Inc.(VERA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction